This website is an information resource intended only for Healthcare Professionals from U.S., Puerto Rico and Canada who are interested in information on Clinical Research and EMD Serono sponsored clinical trials.
By clicking "I am a healthcare professional" you are declaring and confirming that you are a Healthcare Professional inside the U.S., Puerto Rico and Canada and have read and understood this disclaimer.
Immuno-oncology is an innovative approach to cancer therapy that utilizes the body’s own immune system to fight cancer
Advances in the field of immuno-oncology have allowed us to approach cancer therapy in a new and exciting way, with research suggesting we may be able to block immunosuppressive pathways in the tumor microenvironment1
What is bintrafusp alfa?
Bintrafusp alfa is an investigational bifunctional fusion protein currently being investigated for the treatment of various advanced solid tumors
Bintrafusp alfa is designed to simultaneously block two immunosuppressive mechanisms, TGF-β (transforming growth factor β) and PD-L1 (programmed death-ligand 1)2
By targeting these pathways, bintrafusp alfa aims to control tumor growth by potentially restoring and enhancing the anti-tumor response
Rationale for the dual targeting of TGF-β and PD-L1
Bintrafusp alfa is under clinical investigation and has not been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after indication by any health authority worldwide.
1. Finn OJ. Ann Oncol. 2012;23(Suppl 8):6-9.
2. Lan Y, et al. Sci Transl Med. 2018;10:eaan5488.
EMD Serono, a business of Merck KGaA, Darmstadt, Germany and GSK are jointly developing and commercializing bintrafusp alfa as a global strategic alliance.
Bintrafusp alfa is under clinical investigation and has not been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after indication by any health authority worldwide. Clinical trial information is available at www.clinicaltrials.gov.
EMD Serono, a business of Merck KGaA, Darmstadt, Germany will only collect and record your information as it relates to this website. Unless we are subject to other legal commitments, we only use your personal data for the purposes for which you have given your consent. Your personal data will only be shared by us with third parties if that is required in order to provide a service you have requested or if you have given your consent. EMD Serono, a business of Merck KGaA, Darmstadt, Germany will not disclose your personal information to anyone other than contractors who provide services related to this website and are governed by agreements that require personal information to be protected appropriately.
INTR@PID is a registered trademark of Merck KGaA, Darmstadt, Germany